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ABSTRACT
￿
Three mouse monoclonal antibodies, Act I, Act II, and Act IV, against actin from
the cellular slime mold Dictyostelium discoideum, have been made and characterized. All
three antibodies are IgG1 and share the following properties: They form stable complexes
with monomeric Dictyostelium actin, which prevents polymerization of the actin into filaments.
On addition to preformed actin filaments, they cause a reduction in filament size and in the
viscosity of the actin solution. They cross-react strongly with actins from the lower eucaryotes
Physarum and Acanthamoeba, but not with a-actins from rabbit and human muscle or ß- and
y-actins from human erythrocytes and a human B lymphoid cell line. Act II and Act IV
recognize a similar antigenic determinant that is topographically distinct from that identified
by Act I . In protein immunoblotting, only Act I bound strongly to Dictyostelium actin. Analysis
of actin fragments with this technique showed that amino acids 13 to about 50 are required
for Act I binding to actin . A comparison of the amino acid sequences of actins from lower
eucaryotes and higher vertebrates implicates threonine 41 as a critical residue in the Act I
antigenic site. The properties of Act II and Act IV suggest that they recognize antigenic sites
involving the NHz-terminal six residues.
Antibodiesto actin have been difficult to obtain, and this can
be attributed to the high conservation of primary sequence
throughout evolution (see reference 7). To date, most antiac-
tin sera have been produced by animals immunized with
denatured actins: by SDS treatment (19), by precipitation
with alum (14), by chemical cross-linking and modification
with glutaraldehyde (12), or by incubation of G-actin at 4°C
for at least a week (36). In general, the sera obtained have
been of low titer and contain low concentrations of specific
antibody. Despite these limitations, polyclonal sera have been
of use as reagents for localizingactin-containing structures in
cells using immunofluorescence techniques (19). The broad
cross-reactivities ofthese sera with actins from diverse sources
have allowed these studies to be carried out with various cell
types and organisms (e.g., 10).
With specific monoclonal antibodies one may obtain large
amounts of homogeneous antibody directed against single
antigenic determinants (16). It is sometimes possible to use a
weak immune response and obtain high-affinity antibodies
against antigens such as actin that have traditionally proved
to be poorly immunogenic. In addition, hybridoma clones
producing antibodies that recognize different epitopes on the
actin molecule can be selected and used to study the interac-
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tion of actin with the many proteins that appear to regulate
its functional organization in cells(17, 41).
In this report, we describe the preparation and properties
ofthree mouse monoclonal antibodies, Act I, Act II, and Act
IV, against actin from the cellular slime mold, Dictyostelium
discoideum. A preliminary report ofportions ofthis work has
been presented (30).
MATERIALS AND METHODS
Actin
Dictyostelium actin (D. actin)' was prepared by the method ofUyemura et
al. (37). A similar, though scaled-down, procedure was used to prepare
[31S]actin from Dictyostelium (29).
Rabbit skeletal muscle actin was purified from acetone powders using the
method of Spudich and Watt (31) with further purification by chromatography
on diethylaminoethyl (DEAE) cellulose and size exclusioncolumns as described
by Pardee and Spudich (24). Humanmuscleactin wasisolated in the same way
from an acetone powder prepared from thigh muscle tissue (provided by Dr.
R. J. Rouse, Stanford University Medical Center).
Humannonmuscleactin used in these studies was an actin-rich extract of a
human B lymphoblastoid cell line, prepared using the initial steps of the
'Abbreviations used in thispaper:
￿
D. actin, Dictyostelium actin;'H-
IAA, ['H]iodoacetic acid; RIA, radioimmune assay.
287procedure of Uyemura et al. (37). Washed cells were lysed by sonication, and
a high-speed supernatant fraction was prepared by centrifugation at 150,000 g
for 90 min at 4°C. This was chromatographed at 4°C over a Sephadex G-150
superfine column (Pharmacia Fine Chemicals, Piscataway, NJ). Fractions
containing actin as the major band revealed by SDS PAGE were used in the
antibody-binding studies. The actin was >50% of the total protein in the
fraction.
Actins from Acanthamoeba castellanii, Physarum polycephalum,andhuman
erythrocytes were the generous gifts of Dr. T. D. Pollard (The Johns Hopkins
University), Dr. V. T. Nachmias (University of Pennsylvania), and Dr. S. L.
Schrier (Stanford University Medical Center), respectively.
D. actin was radiolabeled with ['H]iodoacetic acid ('H-IAA) as follows. F-
actin in Fbuffer (3 mM triethanolamine-HCI, pH 6.5; 0.2 mM dithiothreitol;
0.5 mM ATP; 0.005% NaN3; 100 mM KCI; 1 mM MgC12) was incubated with
a 20-fold molar excess of 'H-IAA (203 mCi/mmol; New England Nuclear,
Boston, MA) for 9 h at 37°C, then 14 h on ice. After a 24-h dialysis at 4°C
versus two changes of F buffer, the labeled actin was sedimented twice at 30
psi, 20 min in an Airfuge (Beckman Instruments, Inc., Palo Alto, CA) and
finally resuspended in F buffer at 2 mg/ml. The efficiency of labeling ap-
proached I mol of iodoacetate per mol ofactin.
Monoclonal Antibody Production
The strategy and basic methods have been described (25). D. actin at 5 mg/
ml in F buffer was diluted to I mg/ml with PBS and emulsified with an equal
volume of Freund's complete adjuvant. Female BALB/c mice, 4-6 wk of age,
were immunized subcutaneously with 100 til of this emulsion. At 30 and 60 d
the mice were reimmunized with 50 ul of antigen similarly prepared using
Freund's incomplete adjuvant. 1 wk after the third immunization, mice were
bled from the tail and the sera obtained were tested for antiactin antibodies in
an indirect solid-phase radioimmune assay (RIA). The mice were rested for 4
mo and then immunized intravenously on four consecutive days with 25-100
ul of D. actin diluted in PBS as described above. On occasion the intravenous
injection failed and the antigen was then administered intraperitoneally. A
similar immunization schedule was shown by Stdhli et al. (32) to increase the
yield ofspecific hybridomasagainst soluble antigens. On thefifth day the spleen
cellsfrom nine immunized animals were fused with cells ofthe P3/NSI/1-Ag4-
I myeloma line (NSI) (I6) as described (25). Hybridomas were cloned using
the fluorescence-activated cell sorter (Becton Dickinson Immunocytometry
Systems, Mountain View, CA) as modified by Parks et al. (27).
IgG was obtained from ascitic fluids and purified by ammonium sulfate
precipitation and chromatography on Sephadex G-200 and DEAE-cellulose
columns. Purified immunoglobulins were stored frozen in PBS containing0.1
sodium azide as a preservative. F(ab')2 and F(ab) fragments were prepared by
papain degradation (26).
C4 antibody was a gift from Dr. James L. Lessard (Children's Hospital
Research Foundation, Cincinnati, OH). This mouse monoclonal IgGI was
made against actin isolated from chicken gizzard smooth muscle tissue (20).
Antigen-Antibody Binding Assays
SOLID-PHASE RIA :
￿
F-actin from Dictyostelium was diluted to 100-250
ug/ml in PBS N3 (PBS buffer with 0.01 % NaN3) containing 1 mM ATP, and
added to the wells of 96-well polyvinylchloride U-bottom microtiter plates
(Dynatech Laboratories, Inc., Alexandria, VA) at 25 ul per well. Wells to be
used as negative controls contained PBS N3 with 1 % (wt/vol) BSA at 25 ul per
well. Afteran overnight incubation at 4°C in a moist environment, antigen was
removed from the wells, saved, and stored on ice. F-actin solutions were
repeatedly used in the RIA for periods of up to a month. Wells were washed
twice with PBS N3 containing 0.5% BSA. The plates were incubated with the
second wash for 15 min at room temperature in order to saturate all protein-
binding sites. Appropriate dilutions of monoclonal antibodies were added to
the wells and incubated for 2-4 h at room temperature, after which the wells
were washed three times with PBS N3 containing 0.5% BSA. 300,000 cpm
(-0.03 ug)of "I-F(ab')2 rabbit anti-mouse IgG in 25 ul of PBS with 0.5% BSA
were added to each well and incubated for 1-2 h at room temperature. After
four washes with PBS N3 containing 0.5% BSA, the wells were cut from the
plates using a hot wire, and assayed for radioactivity in a Beckman Gamma
4000 (Beckman Instruments Inc., Mountain View, CA).
FORMATION AND ANALYSIS OF IMMUNE COMPLEXES WITH
M ONO M ERIC ACTI N: "S-labeled F-actin was centrifuged for 20 min at 30
psi in an Airfuge. The pellet was resuspended in G buffer (3 mM triethanola-
mine-HCI, pH 7.5; I mM ATP; 0.2 mM dithiothreitol; 0.005% NaN3) con-
taining 0.1% (wt/vol) BSA by sonication for 10 s on ice with a Kontes Micro-
ultrasonic Cell Disruptor (Kontes Glass Co., Vineland, NJ) fitted with a 4.5-in
probe at a power setting of 8 (9.9 W, 25 kHz). After depolymerization of the
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actin on ice for 120 min, the solution was clarified by centrifugation for 60
min at 30 psi in an Airfuge. The concentration of actin monomers in the
supernatant was determined by assaying an aliquot for radioactivity and spec-
trophotometrically using the formula of Gordon et al. (11): Concentration in
mg/mI = (A 290 nm - A 320 nm)/(0.62).
To remove aggregates, we centrifuged solutions ofIgG for 30 min at 30 psi
in an Airfuge. IgG concentrations were determined spectrophotometrically
using the formula: Concentration in mg/m1= A 280 nm x 0.627.
["S]G-actin (25 mg) was incubated overnight on ice with a 10-fold molar
excess ofIgG (893 ug). Controlincubations contained the nonspecific IgG, X63
(16) or no added antibody. 50 u] of dextran blue 2000 (Pharmacia Fine
Chemicals) at 1 mg/ml in G buffer was then added and the samples were
individually applied to a 1.5 x 75-cm column of Sephadex G-150 superfine
resin (Pharmacia Fine Chemicals) in G buffer. Fractions (0.7 ml)were collected
and assayed for ["S]actin by liquid scintillation counting and for absorbance
at 650 rim, to locate the dextran blue which was used as a marker for the void
volume of the column.
Viscometry
Actin assembly and disassembly were measured by high-shear viscometry
performed at 25°C in a Cannon-Manning Semi-micro viscometer, size 100,
with a buffer flow time of 65 s (Cannon Instrument Co., State College, PA).
The specific viscosity (nsp) of the solution was determined from the formula:
i1sp = (flow time sample - flow time buffer)/(flow time buffer).
Proteolytic Cleavages of Actin
Protease from Staphylococcus aureus V8 (Miles Laboratories Inc., Elkhart,
IN), papain (Sigma Chemical Co., St. Louis, MO), and trypsin-N-tosyl-L-
phenylalanine chloromethyl ketone (TPCK)(Worthington Biochemical Corp.,
Freehold, NJ) were used to generate fragments from 'H-labeled D. actin
monomer in G buffer. Cleavage with V8 protease was done in the presence of
0.1% SDS for 60 min at 25°C using enzyme at 1 or 2% (wt/wt) with respect to
actin which was at 500 ug/ml. Papain cleavage was for 15 or 30 min at 25°C
using enzyme at 1 % (wt/wt) with respect to actin. Trypsin-TPCKcleavage was
for 60 minat 25°C using enzyme at 10% (wt/wt)with respect to actin. Reactions
were stopped by boiling with SDS PAGE sample buffer(18).
Hydroxylamine Cleavage of Actin
Treatmentofpolypeptides with hydroxylamine under denaturing conditions
specifically cleaves peptide bonds between asparagine and glycine residues (3).
D. actin contains a single such bond between residues 12 and 13 (40). Actin
monomer labeled with 'H at Cys-373 at 500 ug/ml was incubated in 200 mM
K2C03; 2 M guanidine-HCI; 1 M hydroxylamine; 1 mM ATP at pH 9.0 for 4
h at 45°C. Afterincubation the solution was neutralized with concentrated HCI
and dialyzed overnight at 4°C versus PBS N3 containing I mM ATP.
SDS PAGE, Immunoblotting,
and Autoradiography
The system ofLaemmli (18) was used as described by Ames (1). Molecular
weight markers (Pharmacia Fine Chemicals, Piscataway, NJ) included phos-
phorylase b (94 kilodalton [kD]), BSA (67 kD), ovalbumin (43 kD), carbonic
anhydrase (30 kD), soybean trypsin inhibitor (20.1 kD), and a-lactalbumin
(14.4 kD).
Immunoblotting was performed as described by Towbin et al. (35), except
that all solutions in which the nitrocellulose was incubated contained 0.1%
(vol/vol) Triton X-100 and 0.02% (wt/vol) SDS (8). Samples were electropho-
resed and the gel was cut into replicate slices. One was stained for protein with
Coomassie Brilliant Blue. The other slices were washed with Laemmli (18)
electrode buffer without SDS. Gel slices were then lined up on nitrocellulose
paper (Schleicher & Schuell, Inc., Keene, NH) and proteins were electropho-
resed onto the paper usinga Trans-Blot Cell(Bio-Rad Laboratories, Richmond,
CA). One replicate blot was stained for protein with amido black (0.1 % in 45%
methanol, 10% acetic acid) and then destained in 90% methanol, 2% acetic
acid (28). The other blots were sequentially incubated with solutions containing
BSA (1 h at 37°C)and theneitherantiactinantibody orcontrol immunoglobulin
(X63) (7.5 ug/ml IgG for 14-16 h at room temperature with gentle rotation).
After extensive washing with buffer and buffer containing 0.5 M NaCl, the
papers were incubated for 2 h at room temperature in a solution containing
1 .2 x 106 dpm/mI of '251-F(ab')2 rabbit anti-mouse IgG (-0.08 ug). After five
to six additional washes with bufferthe nitrocellulose paper blots were air dried,
then autoradiographed on Kodak X-OMAT R film (Eastman Kodak Co.,Rochester, NY) at -70°C usinga Cronex Intensifying Screen (Dupont Co.,
Wilmington, DE).
Coomassie Blue-stained gels containing 'H-labeled proteins were prepared
for autoradiographic analysisby treatment with 2,5-diphenyloxazolein DMSO
according to the procedure of Bonner and Laskey (4). Treated gels were dried
onto filter paperand autoradiographed as above.
RESULTS
Monoclonal Antibodies against D. Actin'
The sera from mice immunized with D. actin showed
specific binding to D. actin in a solid-phase RIA. When
compared with sera from unimmunized mice, a specific titer
of about 1 in 1,000 was detected. Specific binding to rabbit
skeletal muscle actin was detected but was very weak com-
pared to D. actin. Spleen cells from nine immunized mice
were individually fused with NS1 myeloma cells and plated
out into a total of 32 24-well plates without feeder cells. In
eight plates no growth of hybrid cells was seen. Vigorous
growth was seen in about one-third ofthe wells ofthe remain-
ing plates and 140 culture supernatants were tested for anti-
bodies against actin. Of these 29 gave binding that was greater
than twice the background value. On subculture, four of the
29 retained activity, and three were subsequently cloned to
give hybridomas Act I, Act II, and Act IV. All three mono-
clonal antibodies were IgG l as shown by RIA using radioio-
dinated goat anti-mouse isotype specific IgG as the second-
step reagents. As actin is known to have significant affinity
for a wide range of proteins including immunoglobulin, it
was important to show that the binding of the monoclonal
antibodies was not a low-affinity "nonspecific" interaction.
This interaction has been characterized by Fechheimer et al.
(9) and probably involves the Ig constant region. The follow-
ing experiments showed this was unlikely as (a) all three
antibodies bound to D. actin but only very weakly to rabbit
skeletal muscle actin, (b) control IgGI with specificity for
human leukocyte antigen molecules gave no binding to actin
in the RIA, (c) soluble D. actin but not rabbit actin could
completely block antibody binding to solid-phase D. actin in
the RIA, (d) no inhibition of monoclonal anti-human leu-
kocyte antigen-binding to solid-phase human leukocyte anti-
gens by D. actin was detected, and (e) the Act antibodies, but
not control IgGI, in conjunction with rabbit anti-mouse IgG
and S. aureus bacteria quantitatively precipitated D. actin
from solution. At this point, each hybridoma was used to
generate an ascitic fluid from which the immunoglobulin was
purified.
Act 1 Identifies a Different Epitope of D . Actin
from Act 11 and Act IV
The topographical relationship of the antigenic determi-
nants (epitopes) of actin bound by Act I, Act II, and Act IV
was investigated by determining if two different monoclonal
2 The hybridoma cells are available from the American Type Culture
Collection Hybridoma Bank, 12301 Parklawn Drive, Rockville, MD
20852.
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FIGURE 1
￿
Two topographically distinct epitopes are recognized by
the three monoclonal antibodies. The binding to D. actin of mixtures
of antibodies in a solid-phase RIA under conditions of antibody
saturation (25 ug/ml). In A the binding of Act I (0) and Act IV (A)
alone are compared with Act I + Act IV (9). B shows the binding of
Act II (0), Act IV (A), Act II + Act IV (0). F(ab)2 fragments were used
to reduce the size of the antibody probes and eliminate nonspecific
binding of actin to the Fc region. 1251-F(ab')2 rabbit anti-mouse IgG
was added at 250,000 dpm/well (0.6 Ag).
antibodies could simultaneously bind to the same actin mol-
ecule. To reduce steric hindrance and nonspecific interaction
between actin and the Fc region, F(ab)2 fragments were used.
Fig. 1 A shows clearly that Act I and Act II antibodies can
bind to D. actin at the same time. In contrast, Act II and Act
IV do not show this additive effect (Fig. 1 B). These results
suggest that Act II and Act IV recognize a closely related site
on the actin molecule that is topographically separate from
that recognized by Act I. In similar experiments, Act I and
Act IV also showed the additive binding behavior. The results
of competition assays, in which dilutions of nonradioactive
Act antibodies were tested for their capacity to inhibit the
binding of radioactive Act antibodies to D. actin, led to the
same conclusions.
Act l, Act 11, and Act IV Bind to Monomeric Actin
Analytical size exclusion column chromatography was used
to show that Act I, Act II, and Act IV bound actin monomers
in solution with high affinity. These results also further sub-
stantiated the combining site specificity ofthe antibodies. Fig.
2 presents elution profiles of "S-labeled actin monomer prein-
cubated with Act I antibody or with the X63 antibody as a
negative control. Actin monomer alone (Fig. 2A) or actin
monomer preincubated with X63 (Fig. 2B)eluted as a single
broad peak within the included volume of the column. In
contrast, when actin monomer was preincubated with the Act
I monoclonal antibody, its elution position shifted markedly
to a narrow peak between tubes 30 and 40, close to the elution
position of the dextran blue (Fig. 2C). Similar results were
obtained with Act II and Act IV. Therefore, in the presence
of Act I, Act II or Act IV monomeric actin chromatographs
as if it were in a high molecular weight complex, i.e., bound
to the antibody. The sharpness of the complex peak and the
lack of a peak due to free actin monomer show that the
interaction between actin monomer and each monoclonal
antibody is ofhigh functional affinity (--10' M-'). From these
experiments one cannot determine if the stability of the
immune complex is purely a result of the affinity between
one antibody combining site and one actin molecule, or if
closed trimolecular complexes between one IgG and two actin
molecules are formed in which actin-actin interactions con-
tribute.
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Electron Microscopy
O 5
Samples placed on carbon-coated grids were negatively stained with I 0
aqueous uranyl acetate (13) and were observed and photographed using a
Philips EM 201 (Philips Electronic Instruments, Inc., Mahwah, NJ) at 80 kV
underconventional operating conditions.0
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FIGURE 3
￿
Effects of antiactin monoclonal antibodies on the polym-
erization of actin monomers into filaments. In these experiments,
the polymerization of monomeric actins was followed with time by
high-shear viscometry. Antibodies were added to the actin before
addition of salts that would favor polymerization. (A) Act IV was
added to D. actin at antibody/actin ratios of: 0.1 (p); 1 :100 (A); 1 :25
("); 1 :10 (A); 1 :5 (O); 1 :2 (0); X63 was added at an antibody/actin
ratio of 1 :2 (/). (J3) Act I was added to rabbit muscle actin at
antibody/actin ratios of: 1 :1 (O); 1 :10 ("); 1 :2 (A). (C) C4 was added
to rabbit muscle actin at antibody/actin ratios of: 0:1 (O); 1 :50 (*);
1 :5 (A). (D) C4 was added to D. actin at antibody/actin ratios of:
0:1 (O); 1 :50 ("); 1 :5 (A).
Act Antibodies Inhibit Formation of F Actin
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As the antibodies bound strongly to monomeric actin it
was possible that they would interfere with actin polymeriza-
tion to form filaments. To address this question, we used
high-shear viscometry, a technique that is sensitive to filament
length, to measure polymerization (15, 23). A series of tubes
containing actin monomer at 250 jug/ml in G buffer was
prepared. Just before the addition of salts (100 mM KCI, 1
MM M9C12, final concentrations), which were used to initiate
filament formation, antiactin antibodies were mixed with the
actin solutions in various molar ratios, and assembly was
followed with time. Fig. 3 shows the results of several ofthese
experiments. In Fig. 3A the antibody used was Act IV. Both
the rate and the extent of assembly decreased as the molar
ratio of antibody increased. At one antibody per two actin
.
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FIGURE 2 Act I antibody and D. actin monomers
form stable complexes as detected by analytical size
exclusion column chromatography. [35S]D. actin
monomer was analyzed on a Sephadex G150 super-
fine column under three conditions: (A) Actin alone;
(8) actin preincubated with a nonspecific IgG1 (X63);
(C) actin preincubated with Act I IgG1 . The arrow in
each panel marks the excluded volume of the col-
umn determined by simultaneous chromatography
of dextran blue.
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FIGURE 4
￿
Act antibodies reduce the viscosity of D. actin filaments
in solution. D. actin monomer at 250,ug/ml in G buffer was induced
to assemble into filaments by the addition of salts at t = 0 (100 mM
KCI, 1 MM M9C12 final concentrations). At the time indicated by
the arrow, Act IV was added at antibody/actin molar ratios of 1 :10
(O); 1 :2 (40). The viscosity of the solution was monitored with time.
monomers, assembly was completely inhibited. In the control
tube, where X63 was mixed with actin monomer at a ratio of
one per two actins, no effect on assembly of filaments was
observed. Act I and Act II yielded identical results to those
obtained with Act IV (data not shown).
Fig. 3 B shows the effect of Act I on the assembly kinetics
of actin from rabbit skeletal muscle. At one antibody per 10
actins there is no noticeable effect; however, assembly was
markedly less complete when the ratio was one antibody per
two actins. As control IgGI (X63) did not inhibit, this result
shows that the monoclonal antibodies do have a low but
specific affinity for rabbit muscle actin. This weak cross-
reactivitycould not be detected by RIA (see Fig. 6).
The effect ofthe cross-reactive monoclonal antiactin C4 on
assembly of D. actin and rabbit actin filaments was also
assessed (Fig. 3 C and D). Even when the antibody was present
at a molar ratio ofone per five actins, there was no effect on
the assembly of either skeletal muscle actin (Fig. 3 C) or D.
actin (Fig. 3D). No decrease in either the rate or extent of
filament formation was observed. In fact, when C4 was pres-
ent at one per five actins, the extent of assembly was slightly
increased over the control.
Act Antibodies Reduce the Size of Preformed
Actin Filaments
High-shear viscometry was also used to assess the effect of
the antiactin antibodies on preformed actin filaments (Fig.
4). When Act IV antibody was added to filaments, there was
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￿
Act antibodies visibly fragmentD . actin filaments in solution . D. actin monomer at 1001ag/ml in G buffer was assembled
into filaments by the addition of salts (100 mM KCI, 1 MM MgCl 2 final concentrations) . The filaments were then treated with
antibodies and prepared for electron microscopy . (a) Control filaments ; no antibody added . (b) X63 IgG added at an antibody/
actin molar ratio of 1 :2 . (c) Act II IgG added at an antibody/actin molar ratio of 1 :2 . (d) Act II Fab added at an antibody fragment/
actin molar ratio of 1 :2 . Bar, 0 .2 um . x 75,000 .
an immediate and significant drop in the viscosity of the
solution. At a molar ratio of one antibody per 10 actins the
reduced viscosity level was maintained with time ; at a ratio
of one antibody per two actins, the viscosity continued to
decrease slowly to very low levels . This suggested that anti-
body binding resulted in filament disruption and that, when
sufficient antibody was present, all the actin could be reduced
to small oligomers or monomers .
A reduction in the high-shear viscosity ofa solution of actin
filaments can be attributed to several factors including fila-
ment shortening, either by fragmentation or by depolymeri-
zation, and filament bundling which effectively reduces the
axial ratio of the particles in solution . To try to distinguish
these possibilities, we observed the effect of antibody on
filaments directlyby electron microscopy ofnegatively stained
specimens (Fig . 5) . In the absence of antibody (Fig . 5 a) or in
the presence ofX63 (Fig. 5 b) the actin filaments were long
and smooth surfaced . When filaments were incubated briefly
with the same amount of an Act antibody, they were seen to
be reduced in size and had a coat of stain-excluding material
that was presumably antibody . This indicated that antibody
was inducing a fragmentation or depolymerization and not a
bundling of actin filaments . To test the role of antibody
bivalency, the experiment was also performed with the Fab
fragment of Act II at a ratio of one fragment per two actins.
In this case the filaments remained intact and were largely
undecorated. It can therefore be concluded that for Act II,
antibody bivalency is necessary for antibody-induced changes
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Cross-reactions ofAct l, Act ll, and Act IV
The RIA was used to assess the reactions of Act I, Act II,
and Act IV with six different actins . Similar patterns of cross-
reaction were obtained for all three antibodies and are illus-
trated for Act I in Fig . 6 . The antibodies bind toD . actin, but
not to rabbit or human skeletal muscle actins (Fig. 6A) .
Although at high antibody concentrations some binding to
muscle actins was seen, this was no greater than the control
where BSA was the plated antigen . In contrast, the antibodies
bound actins from the lower eucaryotes Physarum and Acan-
thamoeba as strongly as they bound D . actin (Fig. 6B).
Nonmuscle actins from erythrocytes and a human lymphoid
cell line showed no more antibody binding than the BSA
control . Therefore, Act I, Act II, and Act IV recognize epitopes
shared by actins from lower eucaryotes, but not by actins
from higher organisms, whether they are of the a-(skeletal
muscle) or ß- and y-(Nonmuscle) isotypes . In contrast, to Act
I, Act II, and Act IV, the C4 monoclonal antibody (Fig . 6C)
bound equivalently to D . actin and rabbit skeletal muscle
actin .
Immunoblot Analysis of
Actin-Antibody Reactions
Protein immunoblotting can be a useful method for local-
izing epitopes inasmuch as it uses the analytical potential of
SDS PAGE. Act I, Act II, and Act IV were therefore tested
for reactivity against D. actin in the immunoblot procedure.
Only Act I gave a strong specific reaction (Fig . 7). The minor
reaction seen with Act IV in Fig . 7 was not considered
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significant inasmuch as the protein standards, phosphorylase
b (94 kD) and carbonic anhydrase (30 kD), showed reactions
of similar magnitude . The mammalian actin preparations
that showed no cross-reactivity in the RIA in Fig. 6 also
showed no specific reaction with Act I on immunoblotting .
The reaction of Act I with D . actin by immunoblotting was
subsequently used to localize a region on theD. actin molecule
required for Act I binding.
Localization ofa Site on Actin Required for Act I
Binding
The strategy was to generate actin fragments and examine
their reactivity with Act I by immunoblotting . The carboxy
terminal region was specifically labeled at Cys-373 with 3H-
IAA, to provide aknown positional marker. Fragments which
retained the 3H label were designated as having retained the
carboxyl terminal and were therefore lacking an amino ter-
minal segment.
3H-LABELING OF ACTIN AND LOCALIZATION OF THE
3H-LABEL : A 20-fold molar excess of 3H-IAA over actin
was used and the incorporation of radioactivity was -5% of
the total, indicating a labeling stoichiometry of close to 1 :1 .
To determine ifthe label was positioned at Cys-373, a tryptic
digestion of the actin was performed and the extent of diges-
tion and release of radioactivity monitored by SDS PAGE
and autoradiography . The carboxyl terminus ofD. actin has
the sequence
-His-Arg-Lys-Cys-Phe-000H
370 371 372 373 374
(40) and -Arg and -Lys are both susceptible to trypsin cleav-
FIGURE 6
￿
Cross-reactions of monoclonal antiactins .
Solid-phase RIAs were as follows : (A), Act I on D.
actin (O), rabbit skeletal muscle a-actin (" ), human
skeletal muscle a-actin (A), BSAW. (B), D . actin (O),
Physarum actin (0), Acanthamoeba actin (A), human
lymphocyte R- and -y-actin (A), human erythrocyte
ß- and y-actin (p) . (C), C4 antibody on D . actin (O),
rabbit skeletal muscle a-actin (0) . Dashed line shows
background binding with BSA as antigen .
FIGURE 7 Act I but not Act II or Act IV
reacts with D . actin in the immunoblot
assay . Lanes 1 and 2, Coomassie Blue-
stained protein gel . Each subsequent pair
of lanes was loaded with replicate samples.
Lane l, molecular weight markers (x10-')
as indicated ; Lane 2, D . actin ; Lanes 3-10,
autoradiograms of ímmunoblots reacted
with Act I (3 and 4), Act II (5 and 6), Act IV
(7 and 8) or X63 (9 and 10) antibodies
followed by "'I-F(ab')z rabbit anti-mouse
IgG ; Lanes 11 and 12, amido black-stained
nitrocellulose blot demonstrating efficient
protein transfer.age resulting in release of label at Cys-373 in a Lys-Cys-Phe
tripeptide. As shown in Fig . 8, all ofthe radioactivity was lost
on tryptic digestion although the mobility of the actin was
not noticeably changed . This strongly suggests that the 3H
label is indeed attached to the actin at Cys-373, because only
a minor cleavage, too small to be seen as a change in electro-
phoretic mobility, was sufficient to remove this label .
CLEAVAGE WITH PROTEASE FROM S . AUREUS V8 :
['H]D. actin was digested with different amounts ofV8 pro-
tease from S. aureus and the fragments were analyzed by SDS
PAGE and either Act I blotting or autoradiography to deter-
mine which fragments retained Cys-373 . As shown in lanes 3
and 4 of Fig. 9 a, a number of discrete fragments were gener-
ated from D. actin . Six major fragments are labeled 1-6 in
Fig . 9 a. The immunoblot (Fig . 9a, lanes 7 and 8) shows that
fragments l, 2, 3, and 5 react with Act 1. The 3H autoradi-
ogram shows that only fragments 4 and 6 retained the car-
boxyl terminus and could therefore be localized within the
molecule . Cleavage from the COON terminus did not result
in the loss of Act I reactivity as evidenced by fragments 1, 2,
3, and 5 . Cleavage from theNHZ terminus resulted in the loss
of Act I reactivity as evidenced by fragments 4 and 6 . Frag-
ment 4 is the largest without Act I reactivity and has an
apparent molecular weight of 25,000 . Therefore, theCOOH
terminal 25kD ofD. actin are not sufficient forAct I reactivity
and this implies that the NHZ terminal 18 kD are important
for Act I binding . From examination of the sequence of D.
actin, one can postulate that the cleavage that generates
fragment 4 is the Glu-Gly bond between residues 167 and
168. This assumes that the V8 protease cleaves specifically at
the carboxyl side of glutamic acid residues .
CLEAVAGE WITH PAPAIN : ['H]D . actin was treated
with papain and the pattern of fragmentation was analyzed
as described in the previous section . The results are in agree-
ment with those obtained with V8 protease . The largest
fragment containing the carboxyl terminus that did not react
with Act I was fragment 1, of apparent molecular weight
37,000 (Fig . 96). This extends the analysis made with V8
protease fragment 4 and suggests that the NH Z terminal 6 kD
ofD . actin are required for binding of Act I in this system .
FIGURE 8 3H-IAA treatment
labels D . actin at Cys-373 . Ra-
diolabeled D . actin monomer
(500 Ag/ml) was incubated
with TPCK-trypsin (50 jug/ml)
for 60 min at 25°C . The reac-
tion was stopped by the addi-
tion of an equal volume of SDS
PAGE sample buffer and boil-
ing for 3 min . Lanes 1-3 and
4-6 are replicates, with the
former showing the Coomas-
sie Blue staining pattern of the
proteins and the latter show-
ing the autoradiogram ob-
tained from a replicate gel
slice treated with 2,5-diphen-
yloxazole . Lanes 1 and 4, mo-
lecularweight markers (x10- ')
as indicated ; Lanes 2 and 5, untreated labeled actin; Lanes 3 and 6,
trypsin-treated labeled actin . Note the absence of radiolabeled
material in lane 6, especially at the position of actin, whereas in
lane 3 there is Coomassie Blue staining material co-migratory with
D. actin .
FIGURE 9 Identification of proteolytic cleavage fragments of D.
actin that react with Act I . 'H-labeled D. actin monomer was treated
with V8 protease (a) or papain (b) and analyzed by SDS PAGE,
autoradiography, and immunoblotting . Replicate sets of four lanes
show Coomassie Blue staining of the gel to detect protein (lanes 1-
4), autoradiography of an immunoblot with Act I and 1251-F(ab') Z
rabbit anti-mouse IgG (lanes 5-8), and autoradiography of the gel
to detect the presence of the 'H-labeled COOH-terminal region
(lanes 9-12) . Lanes 1, 5, and 9 contain standard protein ; lanes 2, 6,
and 10 are untreated ['HID . actin ; lanes 3, 7, and 11 contain
['HID. actin treated with 1% wt/wt V8 protease for 60 min (a) or
with 1% wt/wt papain for 15 min (b) ; in lanes 4, 8, and 12 the
protease treatments were 2% wt/wt V8 for 60 min (a) and 1% wt/
wt papain for 30 min (b) . The molecular weights (x10-3) of protein
standards are shown on the left and the positions of the major
fragments are shown on the right. The use of the same numbers
does not imply identity between the fragments with the same
numbers in a and b .
CLEAVAGE WITH HYDROXYLAMINE : [ 3H]D . actin
was treated with hydroxylamine and the fragments assayed
for retention ofCys-373 and for Act I binding. After treatment
a new species was seen that had a mobility compatible with
the removal ofa small number ofamino acids from the actin
(Fig. 10, lane 4) . The corresponding autoradiogram in Fig.
10, lane 12 shows that this new species retains the carboxyl
terminus. This is consistent with cleavage at the asparagyl-
glycine bond between residues 12 and 13 as previously de-
scribed (3, 34) . The fragment that has lost the first 12 NHZ
terminal amino acids retains reactivity with Act I as shown
in Fig. 10, lane 8 . This result shows that these residues are
not necessary for Act I binding .
SIMPSON ET AL.
￿
MonoclonalAntibody Interaction with Actin
￿
293FIGURE 10 The NH2-terminal 12 residues of D. actin are not re-
quired for Act I binding . 'H-labeled D. actin was treated with
hydroxylamine and the fragments were analyzed by SDS PAGE,
autoradiography, and immunóblotting . Replicate sets of four lanes
show Coomassie Blue staining for protein (lanes 1-4), immunoblot
with Act I and 1251-F(ab')2 rabbit anti-mouse IgG (lanes 5-8), and
autoradiogram of gel to detect the 'H label at residue 373 in the
COOH terminal region (lanes 9-12) . Lanes 1, 5, and 9 contain
protein standards with molecular weights (x10- ') as shown ; lanes
2, 6, and 10 contain untreated actin ; lanes 3, 7, and 11, "mock"-
treated actin, and lanes 4, 8, and 12, hydroxylamine-treated actin .
"Mock" treatment was identical to hydroxylamine treatment except
that hydroxylamine was omitted . The upper arrow on the right
indicates the position of intact actin, the lower arrow the position
ofthe hydroxylamine-generated fragment of an apparent molecular
weight of 42,000 .
Summary of Localization of the Act 1 Binding
Region on D . Actin
Fig. 11 summarizes the analysis of actin fragments for Act
I binding. Cleavage of actin with V8 protease results in the
formation of a 25-kD fragment of actin that has retained the
carboxyl terminus, but has lost the ability to bind Act I
antibody. Cleavage of actin with papain produces a fragment
with similar properties, but with a molecular weight of 37,000.
These results suggest that the amino acids necessary for anti-
body recognition ofthe actin reside in the amino terminal 50
(approximately) residues . However, the hydroxylamine result
indicates that the initial 12 amino terminal residues are not
required for antibody recognition of the actin . In summary,
amino acids from 13 through -50 in the D . actin sequence
are required for binding of the Act I antibody.
The amino acid sequences of actins were compared to
identify substitutions that correlated with the species specific-
ity of Act 1 (6, 22, 38, 39, 40) . In particular, a search was
made for residues that were shared by actins from the lower
eucaryotes and substituted in mammalian actins . Within the
sequence 13-50, there is a single residue that satisfies this
criterion . At position 41 the three lower eucaryotes have
threonine whereas mammalian actins have glutamine . This
suggests that threonine 41 is a critical residue for formation
ofthe Act I antigenic site . As Act I reacts strongly in immu-
noblotting, it is probable that threonine 41 interacts directly
with the Act I combining site . However, the other possibility
that the substitution at position 41 causes a conformational
and antigenic change, at a topographically distinct site that
binds Act I, is not ruled out.
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DISCUSSION
Hyperimmunization ofBALB/c mice with D . actin results in
a significant immune response that was utilized tomake three
monoclonal antibodies, Act I, Act II, and Act IV . The speci-
ficity of these antibodies reflects that of the polyclonal sera in
that they were of high affinity for D. actin and of low affinity
for rabbit skeletal muscle actin . All three antibodies bound
similarly to actins of three lower eucaryotic organisms, Dic-
tyostelium, Physarum, and Acanthamoeba, but did not bind
to a-, Q-, or y-actins from human or rabbit . This species
specificity correlates with the extent of amino acid sequence
homology between the various actins (6, 22, 38, 39, 40) .
Lessard et al. (20) prepared two murine monoclonal antibod-
ies, C4 and B4, against chicken gizzard actin . The C4 antibody
appears to be broadly specific, whereas theB4 antibody reacts
strongly only with muscle actins . Caceres et al . (5) described
two monoclonal antibodies against quail breast actin (QAB1,
QAB2), which do not discriminate between vertebrate actins.
Thus highly specific and broadly specific monoclonal anti-
bodies can be prepared against actins from diverse sources .
The three antibodies, Act I, Act II, and Act IV identify two
topographically distinct epitopes ofthe D. actin molecule; one
recognized by Act I and the other by Act II and Act IV .
Analysis of D . actin fragments by immunoblotting showed
that amino acids 13 to about 50 are required for Act I binding
and that the threonine residue at position 41 is critically
involved in forming the Act I epitope .
The effects the three antibodies have upon the properties
of D. actin have so far been indistinguishable . They form
stable complexes with monomeric actin which prevents the
actin from polymerizing into filaments. Conversely, addition
ofthe antibodies to preformed actin filaments causes them to
become smaller. When a stoichiometric amount of antibody
is added (a) to monomeric actin, polymerization is completely
inhibited, and (b) to filamentous actin, the viscosity is reduced
to the level of monomeric actin . These results show that the
energy gained by forming complexes between antibody and
actin is greater than that gained by forming actin filaments .
The antibodies could interfere with filament formation either
by covering or conformationally altering a site involved in
actin-actin interaction, or by steric hindrance when bound to
a site not involved in actin-actin interaction . The latter is a
serious possibility inasmuch as an antibody molecule is about
3H-IAA
1
H2N
￿
SH
COOH
12-13 -50
￿
-170
￿
373
NH20H Papain
￿
V8 Protease
Region Required
for Act I Binding
Act I Binding
FIGURE 11
￿
Summary of the results of the experiments to localize
the region on D . actin required for Act I antibody binding.three times the size ofan actin monomer. However, the results
with the C4 antibody (Fig. 3 C and D) show that not all
monoclonal antibodies will inhibit actin filament assembly.
The mechanism by which the antibodies depolymerize fila-
ments is not known. It could involve removal of the actin
monomer pool or direct binding to the filaments resulting in
fragmentation within the filament or removal of monomers
from the ends. A cooperative effect between the two combin-
ing sites of the antibody appears to be involved as Fab
fragments of Act II do not affect filament integrity.
A variety of circumstantial evidence suggest that the epi-
topes recognized by Act II and Act IV are formed by residues
in the NH2 terminal region ofthe actin molecule. Combining
the results of crystallographic studies with a study of proteo-
lytic susceptibility Mornet and Ue (21) concluded that actin
consists of a small NH2-terminal domain of -80 residues
linked to a larger COOH-terminal domain that contains the
rest of the molecule. Within the actin filament the small
domains are turned "inward" and the larger domains are
turned "outward" (33). This is consistent with the conclusion
ofBenjamin et al. (2) that antibodies against the NH2-terminal
part ofmonomerc actin do not bind actin filaments whereas
antibodies against the COOH-terminal region do. In keeping
with this picture, and knowing that Act I, Act 11, and Act IV
bind monomer and destroy filaments, one would postulate
that all three antibodies are against epitopes of the smaller
NH2-terminal domain. For Act I, there is independent evi-
dence from the immunoblotting analysis that this is correct.
Ifone assumes it is also true for Act II and Act IV, then what
residues could be involved in their target epitopes? Within
the actin sequence, only residues at positions 2, 5, 6, 41, 234,
295, 297, 306, 317, and 360 fulfill the criterion of being
shared by Dictyostelium, Physarum, and Acanthamoeba ac-
tins and distinct from mammalian actins. Clearly, it is only
the residues at positions 2, 5, 6, and 41 that could be in a
smaller NH2-terminal domain. Inasmuch as Act II and Act
IV are against a topographically different epitope from Act I,
involvement of threonine 41 is excluded. One is thus left with
glycine 2, valine 5, and glutamine 6 as the most likely residues
to be involved in the epitopes recognized by Act II and Act
IV.
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